JP2010514809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514809A5 JP2010514809A5 JP2009544313A JP2009544313A JP2010514809A5 JP 2010514809 A5 JP2010514809 A5 JP 2010514809A5 JP 2009544313 A JP2009544313 A JP 2009544313A JP 2009544313 A JP2009544313 A JP 2009544313A JP 2010514809 A5 JP2010514809 A5 JP 2010514809A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- triazole
- diamine
- pyrimidin
- methylthieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 362
- -1 4,5-dihydro-1H-benzo [b] azepine-2 (3H) -onyl Chemical group 0.000 claims description 352
- 125000001072 heteroaryl group Chemical group 0.000 claims description 197
- 125000000623 heterocyclic group Chemical group 0.000 claims description 186
- 125000000217 alkyl group Chemical group 0.000 claims description 183
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 157
- 125000001188 haloalkyl group Chemical group 0.000 claims description 154
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 149
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 143
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 132
- 229910052739 hydrogen Inorganic materials 0.000 claims description 132
- 239000001257 hydrogen Substances 0.000 claims description 131
- 125000003107 substituted aryl group Chemical group 0.000 claims description 116
- 125000001424 substituent group Chemical group 0.000 claims description 110
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 108
- 150000002431 hydrogen Chemical class 0.000 claims description 100
- 125000002947 alkylene group Chemical group 0.000 claims description 99
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 90
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 82
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 80
- 125000003342 alkenyl group Chemical group 0.000 claims description 73
- 229910052757 nitrogen Inorganic materials 0.000 claims description 64
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims description 50
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 48
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 125000004076 pyridyl group Chemical group 0.000 claims description 43
- 125000004450 alkenylene group Chemical group 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 27
- 125000004043 oxo group Chemical group O=* 0.000 claims description 27
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 25
- 125000004419 alkynylene group Chemical group 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 20
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 19
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 18
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 18
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 16
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims description 16
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 16
- 125000002785 azepinyl group Chemical group 0.000 claims description 13
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 12
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 12
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 claims description 10
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 5
- JIXGIVAJQDTDPH-UHFFFAOYSA-N ClC=1N=C(C2=C(N1)C(=CS2)C)N2N=C(N=C2N)NC=2C=NC=1CCN(CC1C2)C(=O)OCN(C)C Chemical compound ClC=1N=C(C2=C(N1)C(=CS2)C)N2N=C(N=C2N)NC=2C=NC=1CCN(CC1C2)C(=O)OCN(C)C JIXGIVAJQDTDPH-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- CBGPKIVHJMVWJZ-AWEZNQCLSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[(3s)-4-(cyclopropylmethyl)-3-methylpiperazin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C([C@@H]1C)N(C=2N=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=C(Cl)N=3)=CC=2)CCN1CC1CC1 CBGPKIVHJMVWJZ-AWEZNQCLSA-N 0.000 claims description 4
- PVCGZICKHDTJAS-UHFFFAOYSA-N 1-isoquinolin-1-yl-3-n-[2-(pyrrolidin-1-ylmethyl)-1,3-benzoxazol-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2C3=CC=CC=C3C=CN=2)C(N)=NC=1NC(C=C1N=2)=CC=C1OC=2CN1CCCC1 PVCGZICKHDTJAS-UHFFFAOYSA-N 0.000 claims description 4
- 150000004985 diamines Chemical class 0.000 claims description 4
- SZGXBTVBENBHJG-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(1h-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C2NC=CC2=CC(NC2=NN(C(=N2)N)C2=C3SC=C(C3=NC(Cl)=N2)C)=C1 SZGXBTVBENBHJG-UHFFFAOYSA-N 0.000 claims description 3
- NXXRBYJRMCAQHS-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CNCC2=CC(NC3=NN(C(=N3)N)C3=C4SC=C(C4=NC(Cl)=N3)C)=CN=C21 NXXRBYJRMCAQHS-UHFFFAOYSA-N 0.000 claims description 3
- DZRIYKDWJWXKDN-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(6-methyl-7,8-dihydro-5h-1,6-naphthyridin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1=C2CN(C)CCC2=NC=C1NC(=N1)N=C(N)N1C1=NC(Cl)=NC2=C1SC=C2C DZRIYKDWJWXKDN-UHFFFAOYSA-N 0.000 claims description 3
- SWRZSOFOXQXKQW-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(6-pyrrolidin-1-yl-5,6,7,8-tetrahydroquinolin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC2N1CCCC1 SWRZSOFOXQXKQW-UHFFFAOYSA-N 0.000 claims description 3
- PWIDPYCXJIGJCC-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[2-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidin-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CN=C1N(CC1)CCC1N1CCCC1 PWIDPYCXJIGJCC-UHFFFAOYSA-N 0.000 claims description 3
- CGTUNTQVJRTRCD-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCC1N1CCCC1 CGTUNTQVJRTRCD-UHFFFAOYSA-N 0.000 claims description 3
- JKWQKFWORJZXSD-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(1-methylpiperidin-4-yl)-7,8-dihydro-5h-1,6-naphthyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCC1N1CC2=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=C(Cl)N=3)=CN=C2CC1 JKWQKFWORJZXSD-UHFFFAOYSA-N 0.000 claims description 3
- WPYRXIXVWRCXEW-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(4-cyclopentyl-1,4-diazepan-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCCN1C1CCCC1 WPYRXIXVWRCXEW-UHFFFAOYSA-N 0.000 claims description 3
- GMMXICVAAIWGSF-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(4-cyclopropylpiperazin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCN1C1CC1 GMMXICVAAIWGSF-UHFFFAOYSA-N 0.000 claims description 3
- HLCJVMZCBRJAOO-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(4-methylpiperazin-1-yl)-5,6,7,8-tetrahydroquinolin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CC2=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=C(Cl)N=3)=CN=C2CC1 HLCJVMZCBRJAOO-UHFFFAOYSA-N 0.000 claims description 3
- HBNLLUFZTJCVTF-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(4-piperidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1N1CCCCC1 HBNLLUFZTJCVTF-UHFFFAOYSA-N 0.000 claims description 3
- RGWKJDDQLPDDEW-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1N1CCCC1 RGWKJDDQLPDDEW-UHFFFAOYSA-N 0.000 claims description 3
- XPWSIHFLGJXLOU-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[2-(diethylaminomethyl)pyrrolidin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound CCN(CC)CC1CCCN1C(N=C1)=CC=C1NC1=NN(C=2C=3SC=C(C)C=3N=C(Cl)N=2)C(N)=N1 XPWSIHFLGJXLOU-UHFFFAOYSA-N 0.000 claims description 3
- UHOILFJRRJAYEQ-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(C=2N=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=C(Cl)N=3)=CC=2)CC1 UHOILFJRRJAYEQ-UHFFFAOYSA-N 0.000 claims description 3
- MRAHXQIWSUTRMV-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[4-(cyclopropylmethyl)piperazin-1-yl]-5-methylpyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCN1CC1CC1 MRAHXQIWSUTRMV-UHFFFAOYSA-N 0.000 claims description 3
- FUOQPVJSQLUHDX-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[4-(cyclopropylmethyl)piperazin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCN1CC1CC1 FUOQPVJSQLUHDX-UHFFFAOYSA-N 0.000 claims description 3
- UEWDGNZVBNJGNX-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-5-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N1N=C(N)N=C1NC(C=C1C)=CN=C1N(CC1)CCC1N1CCCC1 UEWDGNZVBNJGNX-UHFFFAOYSA-N 0.000 claims description 3
- BMTHCVKOIUTUAN-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCC1N1CCCC1 BMTHCVKOIUTUAN-UHFFFAOYSA-N 0.000 claims description 3
- FWLSDICWESUSSU-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-(4-piperidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1N1CCCCC1 FWLSDICWESUSSU-UHFFFAOYSA-N 0.000 claims description 3
- BEAPWQPYZPDNAI-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1N1CCCC1 BEAPWQPYZPDNAI-UHFFFAOYSA-N 0.000 claims description 3
- XYWYXFYTBXSZED-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-[3-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN(CC1)CCC1N1CCN(C)CC1 XYWYXFYTBXSZED-UHFFFAOYSA-N 0.000 claims description 3
- CZRPGAIKQRBQFR-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1CN1CCCC1 CZRPGAIKQRBQFR-UHFFFAOYSA-N 0.000 claims description 3
- QXYSOIGTSOXRDX-UHFFFAOYSA-N 1-(6-fluoroquinazolin-4-yl)-3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC2=NN(C(N)=N2)C=2C3=CC(F)=CC=C3N=CN=2)=CN=C1N(CC1)CCC1N1CCCC1 QXYSOIGTSOXRDX-UHFFFAOYSA-N 0.000 claims description 3
- XXQCIQWFLCWNKU-UHFFFAOYSA-N 1-[3-[[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]amino]-7,8-dihydro-5h-1,6-naphthyridin-6-yl]-2-(dimethylamino)ethanone Chemical compound C1=C2CN(C(=O)CN(C)C)CCC2=NC=C1NC(=N1)N=C(N)N1C1=NC(Cl)=NC2=C1SC=C2C XXQCIQWFLCWNKU-UHFFFAOYSA-N 0.000 claims description 3
- PEWINDSPAVKYAL-UHFFFAOYSA-N 1-furo[3,2-c]pyridin-4-yl-3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC2=NN(C(N)=N2)C=2C=3C=COC=3C=CN=2)=CN=C1N(CC1)CCC1N1CCCC1 PEWINDSPAVKYAL-UHFFFAOYSA-N 0.000 claims description 3
- RARVFNHZCRECNA-UHFFFAOYSA-N 3-n-(6-benzyl-7,8-dihydro-5h-1,6-naphthyridin-3-yl)-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCN2CC1=CC=CC=C1 RARVFNHZCRECNA-UHFFFAOYSA-N 0.000 claims description 3
- XLFUXAZAZPLMRY-UHFFFAOYSA-N 3-n-(6-bromopyridin-3-yl)-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC1=CC=C(Br)N=C1 XLFUXAZAZPLMRY-UHFFFAOYSA-N 0.000 claims description 3
- VZJOGODJBKWMIF-UHFFFAOYSA-N 3-n-(6-bromopyridin-3-yl)-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC1=CC=C(Br)N=C1 VZJOGODJBKWMIF-UHFFFAOYSA-N 0.000 claims description 3
- OCENWTPHGQLCGO-UHFFFAOYSA-N 3-n-[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-5,6,7,8-tetrahydroquinoline-3,6-diamine Chemical compound C1CC(N)CC2=CC(NC3=NN(C(=N3)N)C3=C4SC=C(C4=NC(Cl)=N3)C)=CN=C21 OCENWTPHGQLCGO-UHFFFAOYSA-N 0.000 claims description 3
- IVTPXGKKEIKMLV-UHFFFAOYSA-N 3-n-[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-6-n-cyclopentyl-5,6,7,8-tetrahydroquinoline-3,6-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC2NC1CCCC1 IVTPXGKKEIKMLV-UHFFFAOYSA-N 0.000 claims description 3
- NBCPDNVLFGOODG-UHFFFAOYSA-N 3-n-[6-[1-(3-bicyclo[2.2.1]heptanyl)piperidin-4-yl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C(CC1)CCN1C1C(C2)CCC2C1 NBCPDNVLFGOODG-UHFFFAOYSA-N 0.000 claims description 3
- TXRZXLPLYFWLGS-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)-1,4-diazepan-1-yl]pyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCCN1C1C(C2)CCC2C1 TXRZXLPLYFWLGS-UHFFFAOYSA-N 0.000 claims description 3
- XINQNGHGVUPKFM-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)piperazin-1-yl]pyridin-3-yl]-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCN1C1C(C2)CCC2C1 XINQNGHGVUPKFM-UHFFFAOYSA-N 0.000 claims description 3
- WZWITAZHJGPHDV-UHFFFAOYSA-N 3-n-[6-[4-(azepan-1-yl)piperidin-1-yl]pyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1N1CCCCCC1 WZWITAZHJGPHDV-UHFFFAOYSA-N 0.000 claims description 3
- JCMXNWCJOIQIGX-UHFFFAOYSA-N 3-n-[6-[4-(cyclopropylmethyl)piperazin-1-yl]-5-methylpyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCN1CC1CC1 JCMXNWCJOIQIGX-UHFFFAOYSA-N 0.000 claims description 3
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 claims description 3
- CAUZWRJVLWSLDN-UHFFFAOYSA-N 5-n-[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-2-n-[2-(diethylamino)ethyl]-2-n-methylpyridine-2,5-diamine Chemical compound C1=NC(N(C)CCN(CC)CC)=CC=C1NC1=NN(C=2C=3SC=C(C)C=3N=C(Cl)N=2)C(N)=N1 CAUZWRJVLWSLDN-UHFFFAOYSA-N 0.000 claims description 3
- XXGMZGGMMCYBET-UHFFFAOYSA-N ClC=1N=C(C2=C(N1)C(=CS2)C)N2N=C(N=C2N)NC=2C=NC=1CCN(CC1C2)C(=O)CC Chemical compound ClC=1N=C(C2=C(N1)C(=CS2)C)N2N=C(N=C2N)NC=2C=NC=1CCN(CC1C2)C(=O)CC XXGMZGGMMCYBET-UHFFFAOYSA-N 0.000 claims description 3
- NLCOHAXBLZXXGN-UHFFFAOYSA-N [3-[[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]amino]-5,6,7,8-tetrahydroquinolin-6-yl]-pyrrolidin-1-ylmethanone Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC2C(=O)N1CCCC1 NLCOHAXBLZXXGN-UHFFFAOYSA-N 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- GYNHVJXRCYEKJE-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(6-cyclopentyl-7,8-dihydro-5h-1,6-naphthyridin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCN2C1CCCC1 GYNHVJXRCYEKJE-UHFFFAOYSA-N 0.000 claims description 2
- XOQNUUOHOAFXRR-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(7-pyrrolidin-1-yl-5,5a,6,7,8,8a-hexahydropentaleno[2,1-b]pyridin-2-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2C3)=CN=C1CC2CC3N1CCCC1 XOQNUUOHOAFXRR-UHFFFAOYSA-N 0.000 claims description 2
- FWTFGHCBZCJPAI-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(cyclopropylmethyl)-7,8-dihydro-5h-1,6-naphthyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCN2CC1CC1 FWTFGHCBZCJPAI-UHFFFAOYSA-N 0.000 claims description 2
- OVCSJJHGWCBDOT-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[2-(dimethylamino)ethyl]-7,8-dihydro-5h-1,6-naphthyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1=C2CN(CCN(C)C)CCC2=NC=C1NC(=N1)N=C(N)N1C1=NC(Cl)=NC2=C1SC=C2C OVCSJJHGWCBDOT-UHFFFAOYSA-N 0.000 claims description 2
- LJWLAGCGLRQAKD-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1CN1CCCC1 LJWLAGCGLRQAKD-UHFFFAOYSA-N 0.000 claims description 2
- RDILVZIOIRILQV-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-spiro[1,3-dioxolane-2,6'-7,8-dihydro-5h-quinoline]-3'-yl-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC12OCCO1 RDILVZIOIRILQV-UHFFFAOYSA-N 0.000 claims description 2
- ULNRKDAJCNVIHR-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[2-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidin-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CN=C1N(CC1)CCC1N1CCCC1 ULNRKDAJCNVIHR-UHFFFAOYSA-N 0.000 claims description 2
- XSBHBXJPXDJWDE-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[2-[4-(piperidin-1-ylmethyl)piperidin-1-yl]pyrimidin-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CN=C1N(CC1)CCC1CN1CCCCC1 XSBHBXJPXDJWDE-UHFFFAOYSA-N 0.000 claims description 2
- YNDFFIDXJGKHOK-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-[3-[3-(dimethylamino)pyrrolidin-1-yl]prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN1CCC(N(C)C)C1 YNDFFIDXJGKHOK-UHFFFAOYSA-N 0.000 claims description 2
- MUCJTZXTUBBCLP-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-[3-[4-(dimethylamino)piperidin-1-yl]prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN1CCC(N(C)C)CC1 MUCJTZXTUBBCLP-UHFFFAOYSA-N 0.000 claims description 2
- CFIZPTWGXUTIGM-UHFFFAOYSA-N 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(6-pyrrolidin-1-yl-5,6,7,8-tetrahydroquinolin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC2N1CCCC1 CFIZPTWGXUTIGM-UHFFFAOYSA-N 0.000 claims description 2
- GEXSWDVMBCCIGR-UHFFFAOYSA-N 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(3-piperidin-1-ylprop-1-enyl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN1CCCCC1 GEXSWDVMBCCIGR-UHFFFAOYSA-N 0.000 claims description 2
- DDQWTKSOVYTDPH-UHFFFAOYSA-N 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(3-pyrrolidin-1-ylprop-1-enyl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN1CCCC1 DDQWTKSOVYTDPH-UHFFFAOYSA-N 0.000 claims description 2
- DBKHGJWJNCXEAZ-UHFFFAOYSA-N 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[3-(4-piperidin-1-ylpiperidin-1-yl)prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN(CC1)CCC1N1CCCCC1 DBKHGJWJNCXEAZ-UHFFFAOYSA-N 0.000 claims description 2
- MZFZRQOOJVTZRE-UHFFFAOYSA-N 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[3-(4-propan-2-ylpiperazin-1-yl)prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C(C)C)CCN1CC=CC(N=C1)=CC=C1NC1=NN(C=2C=3SC=C(C)C=3N=CN=2)C(N)=N1 MZFZRQOOJVTZRE-UHFFFAOYSA-N 0.000 claims description 2
- AAVYTMCAZKRSIF-UHFFFAOYSA-N 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[3-(4-pyrrolidin-1-ylpiperidin-1-yl)prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN(CC1)CCC1N1CCCC1 AAVYTMCAZKRSIF-UHFFFAOYSA-N 0.000 claims description 2
- ZYALZQWEMGUBPL-UHFFFAOYSA-N 3-N-[6-[5-(2-bicyclo[2.2.1]heptanyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-3-yl]pyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C1C2CN(C3C4CCC(C4)C3)CC2CN1 ZYALZQWEMGUBPL-UHFFFAOYSA-N 0.000 claims description 2
- VPVCUVZBSUZTJT-UHFFFAOYSA-N 3-n-(6-cyclopentyl-7,8-dihydro-5h-1,6-naphthyridin-3-yl)-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCN2C1CCCC1 VPVCUVZBSUZTJT-UHFFFAOYSA-N 0.000 claims description 2
- HLTVUFFSYOWGEK-UHFFFAOYSA-N 3-n-[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-6-n-(1-methylpiperidin-4-yl)-5,6,7,8-tetrahydroquinoline-3,6-diamine Chemical compound C1CN(C)CCC1NC1CC2=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=C(Cl)N=3)=CN=C2CC1 HLTVUFFSYOWGEK-UHFFFAOYSA-N 0.000 claims description 2
- QDGXQAZPANHFQZ-UHFFFAOYSA-N 3-n-[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-6-n-cyclohexyl-5,6,7,8-tetrahydroquinoline-3,6-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC2NC1CCCCC1 QDGXQAZPANHFQZ-UHFFFAOYSA-N 0.000 claims description 2
- CVJCSJWHJYHENE-UHFFFAOYSA-N 3-n-[5-amino-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-6-n-(1-methylpiperidin-4-yl)-5,6,7,8-tetrahydroquinoline-3,6-diamine Chemical compound C1CN(C)CCC1NC1CC2=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=CN=3)=CN=C2CC1 CVJCSJWHJYHENE-UHFFFAOYSA-N 0.000 claims description 2
- MANZRMPIGJYTAM-UHFFFAOYSA-N 3-n-[5-amino-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-6-n-cyclopentyl-5,6,7,8-tetrahydroquinoline-3,6-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC2NC1CCCC1 MANZRMPIGJYTAM-UHFFFAOYSA-N 0.000 claims description 2
- YZSQHSFTMIMDGT-UHFFFAOYSA-N 3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1-(2-methylquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=12C=CC=CC2=NC(C)=NC=1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCC1N1CCCC1 YZSQHSFTMIMDGT-UHFFFAOYSA-N 0.000 claims description 2
- LZFAFFGAFUYSFW-UHFFFAOYSA-N 3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1-(6-phenylpyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=1N=C(N2CCC(CC2)N2CCCC2)C(C)=CC=1NC(=N1)N=C(N)N1C(N=CN=1)=CC=1C1=CC=CC=C1 LZFAFFGAFUYSFW-UHFFFAOYSA-N 0.000 claims description 2
- RPABPCZXGRYRDY-UHFFFAOYSA-N 3-n-[6-(3-bicyclo[2.2.1]heptanyl)-7,8-dihydro-5h-1,6-naphthyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCN2C1C(C2)CCC2C1 RPABPCZXGRYRDY-UHFFFAOYSA-N 0.000 claims description 2
- FBPLYLVFMMPBQR-UHFFFAOYSA-N 3-n-[6-(4-cyclopentyl-1,4-diazepan-1-yl)pyridin-3-yl]-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCCN1C1CCCC1 FBPLYLVFMMPBQR-UHFFFAOYSA-N 0.000 claims description 2
- ASWPQGIBBVOHPZ-INIZCTEOSA-N 3-n-[6-[(3s)-4-(cyclopropylmethyl)-3-methylpiperazin-1-yl]pyridin-3-yl]-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(C[C@@H]1C)CCN1CC1CC1 ASWPQGIBBVOHPZ-INIZCTEOSA-N 0.000 claims description 2
- ODTZSCMUQHPIPC-HNNXBMFYSA-N 3-n-[6-[(3s)-4-(cyclopropylmethyl)-3-methylpiperazin-1-yl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C([C@@H]1C)N(C=2N=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=CN=3)=CC=2)CCN1CC1CC1 ODTZSCMUQHPIPC-HNNXBMFYSA-N 0.000 claims description 2
- YQBRDGJLCFPLEY-JTJHWIPRSA-N 3-n-[6-[(3s)-4-[(1r,3s,4s)-3-bicyclo[2.2.1]heptanyl]-3-methylpiperazin-1-yl]-5-methylpyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N([C@@H]1[C@@]2([H])CC[C@](C2)(C1)[H])([C@H](C1)C)CCN1C(C(=C1)C)=NC=C1NC(=N1)N=C(N)N1C1=NC=NC2=C1SC=C2C YQBRDGJLCFPLEY-JTJHWIPRSA-N 0.000 claims description 2
- VHGREDURKMTEHO-NNZWXOEDSA-N 3-n-[6-[(3s)-4-[(3s)-3-bicyclo[2.2.1]heptanyl]-3-methylpiperazin-1-yl]-5-methylpyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C([C@@H](N(CC1)[C@@H]2C3CCC(C3)C2)C)N1C(C(=C1)C)=NC=C1NC(=N1)N=C(N)N1C1=NC(Cl)=NC2=C1SC=C2C VHGREDURKMTEHO-NNZWXOEDSA-N 0.000 claims description 2
- SLIFFOFIRQCBER-RJPLPAITSA-N 3-n-[6-[(3s)-4-[(3s)-3-bicyclo[2.2.1]heptanyl]-3-methylpiperazin-1-yl]-5-methylpyridin-3-yl]-1-thieno[3,2-d]pyrimidin-4-yl-1,2,4-triazole-3,5-diamine Chemical compound C([C@@H](N(CC1)[C@@H]2C3CCC(C3)C2)C)N1C(C(=C1)C)=NC=C1NC(=N1)N=C(N)N1C1=NC=NC2=C1SC=C2 SLIFFOFIRQCBER-RJPLPAITSA-N 0.000 claims description 2
- AGTXUSZAASMJMA-UHFFFAOYSA-N 3-n-[6-[1-(3-bicyclo[2.2.1]heptanyl)piperidin-4-yl]pyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C(CC1)CCN1C1C(C2)CCC2C1 AGTXUSZAASMJMA-UHFFFAOYSA-N 0.000 claims description 2
- VDQIHMZMVRCPCP-UHFFFAOYSA-N 3-n-[6-[2-(diethylaminomethyl)pyrrolidin-1-yl]pyridin-3-yl]-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound CCN(CC)CC1CCCN1C(N=C1)=CC=C1NC1=NN(C=2C3=CC(OC)=C(OC)C=C3N=CN=2)C(N)=N1 VDQIHMZMVRCPCP-UHFFFAOYSA-N 0.000 claims description 2
- MCZIQOYTHMZUKK-UHFFFAOYSA-N 3-n-[6-[3-(4-cyclopentylpiperazin-1-yl)prop-1-enyl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN(CC1)CCN1C1CCCC1 MCZIQOYTHMZUKK-UHFFFAOYSA-N 0.000 claims description 2
- YLWDXZGPODUNRE-UHFFFAOYSA-N 3-n-[6-[3-(4-methylpiperazin-1-yl)prop-1-enyl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1CC=CC(N=C1)=CC=C1NC1=NN(C=2C=3SC=C(C)C=3N=CN=2)C(N)=N1 YLWDXZGPODUNRE-UHFFFAOYSA-N 0.000 claims description 2
- VASQQTJSFJZLPX-UHFFFAOYSA-N 3-n-[6-[3-[3-(diethylamino)pyrrolidin-1-yl]prop-1-enyl]pyridin-3-yl]-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1C(N(CC)CC)CCN1CC=CC(N=C1)=CC=C1NC1=NN(C=2C3=CC(OC)=C(OC)C=C3N=CN=2)C(N)=N1 VASQQTJSFJZLPX-UHFFFAOYSA-N 0.000 claims description 2
- FJZFCZBKTPYPHL-UHFFFAOYSA-N 3-n-[6-[3-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]prop-1-enyl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(CC=CC=2N=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=CN=3)=CC=2)CC1 FJZFCZBKTPYPHL-UHFFFAOYSA-N 0.000 claims description 2
- HNNAJWPDLMIYOJ-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)-1,4-diazepan-1-yl]pyridin-3-yl]-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCCN1C1C(C2)CCC2C1 HNNAJWPDLMIYOJ-UHFFFAOYSA-N 0.000 claims description 2
- LRRZKAYPGFPVSE-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)piperazin-1-yl]-5-methylpyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCN1C1C(C2)CCC2C1 LRRZKAYPGFPVSE-UHFFFAOYSA-N 0.000 claims description 2
- GQONIVGBMPPYLT-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)piperazin-1-yl]-5-methylpyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCN1C1C(C2)CCC2C1 GQONIVGBMPPYLT-UHFFFAOYSA-N 0.000 claims description 2
- GJGJAZOOIBLDRR-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)piperazin-1-yl]pyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCN1C1C(C2)CCC2C1 GJGJAZOOIBLDRR-UHFFFAOYSA-N 0.000 claims description 2
- MIMDPEPFDUHCJI-LQWHRVPQSA-N 3-n-[6-[4-[(1r,3s,4s)-3-bicyclo[2.2.1]heptanyl]piperazin-1-yl]-5-methylpyridin-3-yl]-1-(4-methylthieno[2,3-d]pyridazin-7-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CN([C@@H]2[C@@]3([H])CC[C@](C3)(C2)[H])CCN1C(C(=C1)C)=NC=C1NC(=N1)N=C(N)N1C1=NN=C(C)C2=C1SC=C2 MIMDPEPFDUHCJI-LQWHRVPQSA-N 0.000 claims description 2
- UVSTTXHREXRJGZ-AOIWGVFYSA-N 3-n-[6-[4-[(1r,3s,4s)-3-bicyclo[2.2.1]heptanyl]piperazin-1-yl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CN([C@@H]2[C@@]3([H])CC[C@](C3)(C2)[H])CCN1C(N=C1)=CC=C1NC(=N1)N=C(N)N1C1=NC=NC2=C1SC=C2C UVSTTXHREXRJGZ-AOIWGVFYSA-N 0.000 claims description 2
- SGRCMYYRCYSMFQ-RJYAGPCLSA-N 3-n-[6-[4-[(3s)-3-bicyclo[2.2.1]heptanyl]piperazin-1-yl]-5-chloropyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1Cl)=CN=C1N(CC1)CCN1[C@@H]1C(C2)CCC2C1 SGRCMYYRCYSMFQ-RJYAGPCLSA-N 0.000 claims description 2
- GQONIVGBMPPYLT-QLOJAFMTSA-N 3-n-[6-[4-[(3s)-3-bicyclo[2.2.1]heptanyl]piperazin-1-yl]-5-methylpyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C)=CN=C1N(CC1)CCN1[C@@H]1C(C2)CCC2C1 GQONIVGBMPPYLT-QLOJAFMTSA-N 0.000 claims description 2
- DVFGVWXLVOBWFW-UHFFFAOYSA-N 5-n-[5-amino-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazol-3-yl]-2-n-[2-(diethylamino)ethyl]-2-n-methylpyridine-2,5-diamine Chemical compound C1=NC(N(C)CCN(CC)CC)=CC=C1NC1=NN(C=2C3=CC(OC)=C(OC)C=C3N=CN=2)C(N)=N1 DVFGVWXLVOBWFW-UHFFFAOYSA-N 0.000 claims description 2
- QSSRJKUHUMTOSV-LQWHRVPQSA-N 5-n-[6-[4-[(1r,3s,4s)-3-bicyclo[2.2.1]heptanyl]piperazin-1-yl]-5-methylpyridin-3-yl]-1-(4-methylthieno[2,3-d]pyridazin-7-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CN([C@@H]2[C@@]3([H])CC[C@](C3)(C2)[H])CCN1C(C(=C1)C)=NC=C1NC1=NC(N)=NN1C1=NN=C(C)C2=C1SC=C2 QSSRJKUHUMTOSV-LQWHRVPQSA-N 0.000 claims description 2
- HONQXNBUCHWQJD-UHFFFAOYSA-N [3-[[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]amino]-7,8-dihydro-5h-1,6-naphthyridin-6-yl]-(1-methylpiperidin-4-yl)methanone Chemical compound C1CN(C)CCC1C(=O)N1CC2=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=C(Cl)N=3)=CN=C2CC1 HONQXNBUCHWQJD-UHFFFAOYSA-N 0.000 claims description 2
- ORNYWWRXXZWHTG-UHFFFAOYSA-N [3-[[5-amino-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]amino]-7,8-dihydro-5h-1,6-naphthyridin-6-yl]-(1-methylpiperidin-4-yl)methanone Chemical compound C1CN(C)CCC1C(=O)N1CC2=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=CN=3)=CN=C2CC1 ORNYWWRXXZWHTG-UHFFFAOYSA-N 0.000 claims description 2
- YXDSSFSHHWTVOE-UHFFFAOYSA-N [5-[[5-amino-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazol-3-yl]amino]-1-benzothiophen-2-yl]-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]methanone Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=C1C=2)=CC=C1SC=2C(=O)N1CCN(CCN(C)C)CC1 YXDSSFSHHWTVOE-UHFFFAOYSA-N 0.000 claims description 2
- BUVPFCDSSMYVCI-UHFFFAOYSA-N n-[3-[[5-amino-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]amino]-5,6,7,8-tetrahydroquinolin-6-yl]-1-methylpiperidine-4-carboxamide Chemical compound C1CN(C)CCC1C(=O)NC1CC2=CC(NC3=NN(C(N)=N3)C=3C=4SC=C(C)C=4N=CN=3)=CN=C2CC1 BUVPFCDSSMYVCI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 24
- BXIOWKCYAMEFSI-UHFFFAOYSA-N 1-(7,8-dihydro-6h-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-yl)-3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC2=NN(C(N)=N2)C=2C=3C=4CCCC=4SC=3N=CN=2)=CN=C1N(CC1)CCC1N1CCCC1 BXIOWKCYAMEFSI-UHFFFAOYSA-N 0.000 claims 1
- YBWIFXFCMGJYFE-UHFFFAOYSA-N 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(3-morpholin-4-ylprop-1-enyl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=CN=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN1CCOCC1 YBWIFXFCMGJYFE-UHFFFAOYSA-N 0.000 claims 1
- BCXSZQWGNJAZMA-UHFFFAOYSA-N 3-n-[6-[1-(3-bicyclo[2.2.1]heptanyl)-3-methylpiperidin-4-yl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound CC1CN(C2C3CCC(C3)C2)CCC1C(N=C1)=CC=C1NC(=N1)N=C(N)N1C1=NC=NC2=C1SC=C2C BCXSZQWGNJAZMA-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 143
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 112
- 238000005481 NMR spectroscopy Methods 0.000 description 59
- 125000005843 halogen group Chemical group 0.000 description 57
- 125000003118 aryl group Chemical group 0.000 description 54
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- 238000000034 method Methods 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- 150000003254 radicals Chemical class 0.000 description 24
- 125000004432 carbon atom Chemical group C* 0.000 description 22
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- 125000000753 cycloalkyl group Chemical group 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 201000009273 Endometriosis Diseases 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 238000010172 mouse model Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 239000011534 wash buffer Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 150000003852 triazoles Chemical class 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 208000024248 Vascular System injury Diseases 0.000 description 6
- 208000012339 Vascular injury Diseases 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 208000002780 macular degeneration Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 5
- 206010023439 Kidney transplant rejection Diseases 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 5
- 201000005969 Uveal melanoma Diseases 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 208000025113 myeloid leukemia Diseases 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910052717 sulfur Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 208000029257 vision disease Diseases 0.000 description 4
- JXEONDIXVBORTQ-UHFFFAOYSA-N 2-(pyrrolidin-1-ylmethyl)-1,3-benzoxazol-5-amine Chemical compound N=1C2=CC(N)=CC=C2OC=1CN1CCCC1 JXEONDIXVBORTQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101150022345 GAS6 gene Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000033781 Thyroid carcinoma Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000005593 norbornanyl group Chemical group 0.000 description 3
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 201000010174 renal carcinoma Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- ZMXIVPGZNNLQMQ-UHFFFAOYSA-N 1-isoquinolin-1-yl-3-n-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NN(C=2C3=CC=CC=C3C=CN=2)C(N)=N1 ZMXIVPGZNNLQMQ-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- UIBUTEMKCCXAQO-UHFFFAOYSA-N 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(6,7-dimethoxyquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine Chemical compound O1C2=C(OCC1)C=C(C=C2)C2(NN(C(=N2)N)C2=NC=NC1=CC(=C(C=C21)OC)OC)N UIBUTEMKCCXAQO-UHFFFAOYSA-N 0.000 description 2
- DJPWIONGBKUGNZ-UHFFFAOYSA-N 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-isoquinolin-1-yl-1H-1,2,4-triazole-3,5-diamine Chemical compound O1C2=C(OCC1)C=C(C=C2)C2(NN(C(=N2)N)C2=NC=CC1=CC=CC=C21)N DJPWIONGBKUGNZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000650322 Homo sapiens E3 ubiquitin-protein ligase Arkadia Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101150098329 Tyro3 gene Proteins 0.000 description 2
- PUTFYDYKYCMXHZ-UHFFFAOYSA-N [3-[[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]amino]-7,8-dihydro-5h-1,6-naphthyridin-6-yl]-piperidin-4-ylmethanone Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCN2C(=O)C1CCNCC1 PUTFYDYKYCMXHZ-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000005015 aryl alkynyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- QXEIZLFZKCUTMG-UHFFFAOYSA-N phenyl n-cyano-n'-[2-(pyrrolidin-1-ylmethyl)-1,3-benzoxazol-5-yl]carbamimidate Chemical compound C=1C=CC=CC=1OC(=N/C#N)\NC(C=C1N=2)=CC=C1OC=2CN1CCCC1 QXEIZLFZKCUTMG-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- RWSGMFHJSIEOLZ-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(7-cyclopentyl-5,6,8,9-tetrahydropyrido[2,3-d]azepin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1CC2)=CN=C1CCN2C1CCCC1 RWSGMFHJSIEOLZ-UHFFFAOYSA-N 0.000 description 1
- QYUBPVPPQRJCQU-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1CC2)=CN=C1CCC2N1CCCC1 QYUBPVPPQRJCQU-UHFFFAOYSA-N 0.000 description 1
- XWPAAJDGNIMUTB-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[2-[4-(piperidin-1-ylmethyl)piperidin-1-yl]pyrimidin-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=N1)=CN=C1N(CC1)CCC1CN1CCCCC1 XWPAAJDGNIMUTB-UHFFFAOYSA-N 0.000 description 1
- VDPVAYDKOMDMHA-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NN(C=2C=3SC=C(C)C=3N=C(Cl)N=2)C(N)=N1 VDPVAYDKOMDMHA-UHFFFAOYSA-N 0.000 description 1
- ONDJRPMCKZZNCN-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-[6-[3-(diethylamino)pyrrolidin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1C(N(CC)CC)CCN1C(N=C1)=CC=C1NC1=NN(C=2C=3SC=C(C)C=3N=C(Cl)N=2)C(N)=N1 ONDJRPMCKZZNCN-UHFFFAOYSA-N 0.000 description 1
- LNZWXPRLORWMIK-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-[3-(4-propan-2-ylpiperazin-1-yl)prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN1CCN(C(C)C)CC1 LNZWXPRLORWMIK-UHFFFAOYSA-N 0.000 description 1
- UVYIBHDJDJMPDO-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-[6-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1N(CC1)CCC1N1CCN(C)CC1 UVYIBHDJDJMPDO-UHFFFAOYSA-N 0.000 description 1
- MXVTUUXJXGDKJQ-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-spiro[1,3-dioxolane-2,6'-5,7,8,9-tetrahydrocyclohepta[b]pyridine]-3'-yl-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCCC12OCCO1 MXVTUUXJXGDKJQ-UHFFFAOYSA-N 0.000 description 1
- XXDWPJATMHZZOJ-UHFFFAOYSA-N 1-(6-chloroquinazolin-4-yl)-3-n-[2-(pyrrolidin-1-ylmethyl)-1,3-benzoxazol-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2C3=CC(Cl)=CC=C3N=CN=2)C(N)=NC=1NC(C=C1N=2)=CC=C1OC=2CN1CCCC1 XXDWPJATMHZZOJ-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- XYDXCXOYCUWHKI-UHFFFAOYSA-N 1-isoquinolin-1-yl-3-n-(6-methyl-7,8-dihydro-5h-1,6-naphthyridin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1=CC=C2C(N3C(N)=NC(=N3)NC3=CN=C4CCN(CC4=C3)C)=NC=CC2=C1 XYDXCXOYCUWHKI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical compound COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PVCMPDPASFANBH-UHFFFAOYSA-N 3-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(C2(N)N=C(N)NN2)=CN=C1N(CC1)CCC1N1CCCC1 PVCMPDPASFANBH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- XAHPSZGSIHQJFE-UHFFFAOYSA-N 3-n-[5-amino-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazol-3-yl]-6-n,6-n-bis(cyclopropylmethyl)-5,6,7,8-tetrahydroquinoline-3,6-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCC2N(CC1CC1)CC1CC1 XAHPSZGSIHQJFE-UHFFFAOYSA-N 0.000 description 1
- NMGQAQJFYKOHGZ-UHFFFAOYSA-N 3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1-phenanthridin-6-yl-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC2=NN(C(N)=N2)C=2C3=CC=CC=C3C3=CC=CC=C3N=2)=CN=C1N(CC1)CCC1N1CCCC1 NMGQAQJFYKOHGZ-UHFFFAOYSA-N 0.000 description 1
- LZVQKPFXHCCQNT-UHFFFAOYSA-N 3-n-[6-[3-(4-cyclopentylpiperazin-1-yl)prop-1-enyl]pyridin-3-yl]-1-(6,7-dimethoxyquinazolin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=N1)=CC=C1C=CCN(CC1)CCN1C1CCCC1 LZVQKPFXHCCQNT-UHFFFAOYSA-N 0.000 description 1
- SHQULDBQQSAFTF-UHFFFAOYSA-N 3-n-[6-[4-(cyclopropylmethyl)piperazin-1-yl]pyridin-3-yl]-1-[5-(trifluoromethyl)pyridin-2-yl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=CC(=CC=2)C(F)(F)F)C(N)=NC=1NC(C=N1)=CC=C1N(CC1)CCN1CC1CC1 SHQULDBQQSAFTF-UHFFFAOYSA-N 0.000 description 1
- WZXBXKXZFBJWLU-UVXJWDRCSA-N 3-n-[6-[4-[(1r,3s,4s)-3-bicyclo[2.2.1]heptanyl]piperazin-1-yl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CN([C@@H]2[C@@]3([H])CC[C@](C3)(C2)[H])CCN1C(N=C1)=CC=C1NC(=N1)N=C(N)N1C1=NC=NC2=C1SC=C2C WZXBXKXZFBJWLU-UVXJWDRCSA-N 0.000 description 1
- DPJFUERCQGZGNS-JMLCCBQJSA-N 3-n-[6-[4-[(3s)-3-bicyclo[2.2.1]heptanyl]piperazin-1-yl]-5-chloropyridin-3-yl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1Cl)=CN=C1N(CC1)CCN1[C@@H]1C(C2)CCC2C1 DPJFUERCQGZGNS-JMLCCBQJSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- LJCUAVLFJVLKDZ-UHFFFAOYSA-N 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-phenyl-1H-1,2,4-triazole-3,5-diamine Chemical compound O1C2=C(OCC1)C=C(C=C2)C2(NN(C(=N2)N)C2=CC=CC=C2)N LJCUAVLFJVLKDZ-UHFFFAOYSA-N 0.000 description 1
- XQKZWWGOMGCHNR-UHFFFAOYSA-N 5-n-[6-[3-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]prop-1-enyl]pyridin-3-yl]-1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(CC=CC=2N=CC(NC=3N(N=C(N)N=3)C=3C=4SC=C(C)C=4N=CN=3)=CC=2)CC1 XQKZWWGOMGCHNR-UHFFFAOYSA-N 0.000 description 1
- BUVKVCXJRYKNPD-UHFFFAOYSA-N 5-nitro-2-(pyrrolidin-1-ylmethyl)-1,3-benzoxazole Chemical compound N=1C2=CC([N+](=O)[O-])=CC=C2OC=1CN1CCCC1 BUVKVCXJRYKNPD-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HEOQXHNKRXRCTO-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulene Chemical compound C1CCCCC2=CC=CC=C21 HEOQXHNKRXRCTO-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OTNPWKRCFFANQV-UHFFFAOYSA-N CC1=CSC(C(N2N=C(C(NC3=CN=C(CCC4(CC5)OCCO4)C5=C3)=N)N=C2C(N)=N)=N2)=C1N=C2Cl Chemical compound CC1=CSC(C(N2N=C(C(NC3=CN=C(CCC4(CC5)OCCO4)C5=C3)=N)N=C2C(N)=N)=N2)=C1N=C2Cl OTNPWKRCFFANQV-UHFFFAOYSA-N 0.000 description 1
- CCCMIQGKAABVFT-UHFFFAOYSA-N CC1=CSC(C(N2N=C(C(NC3=CN=C(CCCC4(C5)OCCO4)C5=C3)=N)N=C2C(N)=N)=N2)=C1N=C2Cl Chemical compound CC1=CSC(C(N2N=C(C(NC3=CN=C(CCCC4(C5)OCCO4)C5=C3)=N)N=C2C(N)=N)=N2)=C1N=C2Cl CCCMIQGKAABVFT-UHFFFAOYSA-N 0.000 description 1
- XTOWNTUJUPTONA-UHFFFAOYSA-N CC1CN(CCC1c1ccc(cn1)-n1nc(N)nc1N)C1CC2CCC1C2 Chemical compound CC1CN(CCC1c1ccc(cn1)-n1nc(N)nc1N)C1CC2CCC1C2 XTOWNTUJUPTONA-UHFFFAOYSA-N 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 description 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- FEKZQJQONSSAPZ-UHFFFAOYSA-N Nc1nc(N)n(n1)-c1ccc(C=CCN2CCOCC2)nc1 Chemical compound Nc1nc(N)n(n1)-c1ccc(C=CCN2CCOCC2)nc1 FEKZQJQONSSAPZ-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 101150027040 axl-1 gene Proteins 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 150000001949 daidzein Chemical class 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000003121 in-cell western assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- IOOUWJDACLDFNP-UHFFFAOYSA-N isoquinolin-1-ylhydrazine Chemical compound C1=CC=C2C(NN)=NC=CC2=C1 IOOUWJDACLDFNP-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88287506P | 2006-12-29 | 2006-12-29 | |
| US60/882,875 | 2006-12-29 | ||
| US97544307P | 2007-09-26 | 2007-09-26 | |
| US60/975,443 | 2007-09-26 | ||
| PCT/US2007/089153 WO2008083354A1 (en) | 2006-12-29 | 2007-12-28 | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014024758A Division JP5890445B2 (ja) | 2006-12-29 | 2014-02-12 | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514809A JP2010514809A (ja) | 2010-05-06 |
| JP2010514809A5 true JP2010514809A5 (enExample) | 2013-09-12 |
| JP5567837B2 JP5567837B2 (ja) | 2014-08-06 |
Family
ID=39203174
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544313A Expired - Fee Related JP5567837B2 (ja) | 2006-12-29 | 2007-12-28 | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール |
| JP2014024758A Expired - Fee Related JP5890445B2 (ja) | 2006-12-29 | 2014-02-12 | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014024758A Expired - Fee Related JP5890445B2 (ja) | 2006-12-29 | 2014-02-12 | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9650391B2 (enExample) |
| EP (2) | EP2074115B1 (enExample) |
| JP (2) | JP5567837B2 (enExample) |
| CN (1) | CN101622248B (enExample) |
| AU (1) | AU2007342005A1 (enExample) |
| CA (1) | CA2710046C (enExample) |
| ES (2) | ES2672172T3 (enExample) |
| WO (1) | WO2008083354A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| CA2710230C (en) | 2006-12-29 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
| ES2558477T3 (es) | 2006-12-29 | 2016-02-04 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos útiles como inhibidores de AXL |
| PL2078010T3 (pl) | 2006-12-29 | 2014-07-31 | Rigel Pharmaceuticals Inc | Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl |
| US9650391B2 (en) * | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
| SI2205592T1 (sl) * | 2007-10-26 | 2013-09-30 | Rigel Pharmaceuticals, Inc. | Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji |
| MX2010008926A (es) | 2008-02-15 | 2011-02-23 | Rigel Pharmaceuticals Inc | Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas. |
| EP2326641B1 (en) | 2008-07-09 | 2014-09-03 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2730251C (en) | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| US8546433B2 (en) * | 2009-01-16 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| HUE031624T2 (en) | 2012-01-31 | 2017-07-28 | Daiichi Sankyo Co Ltd | Pyridone derivative |
| US20150164800A1 (en) | 2012-07-25 | 2015-06-18 | Xetrios Therapeutics, Inc. | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine |
| GB201213556D0 (en) | 2012-07-31 | 2012-09-12 | Luminectric Ltd | Cases for portable electronic devices |
| AU2014353006B2 (en) | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
| JP6496731B2 (ja) | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation | Tamファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
| TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| JP6885390B2 (ja) | 2016-02-26 | 2021-06-16 | 小野薬品工業株式会社 | Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
| HRP20231614T1 (hr) | 2016-03-28 | 2024-03-15 | Incyte Corporation | Spojevi pirolotriazina kao tam inhibitori |
| WO2019039525A1 (ja) | 2017-08-23 | 2019-02-28 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
| WO2019067594A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS |
| WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
| MX2021000127A (es) | 2018-06-29 | 2021-03-29 | Incyte Corp | Formulaciones de un inhibidor de axl/mer. |
| MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| MX2022010860A (es) | 2020-03-06 | 2022-12-02 | Incyte Corp | Terapia combinada que comprende inhibidores de axl/mer y pd-1/pd-l1. |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| KR20230013241A (ko) | 2020-04-08 | 2023-01-26 | 베르겐바이오 에이에스에이 | 항바이러스 요법을 위한 axl 억제제 |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| WO2024051667A1 (zh) * | 2022-09-05 | 2024-03-14 | 南京正大天晴制药有限公司 | 具有axl抑制活性的取代三唑化合物 |
| CN121039109A (zh) * | 2023-04-18 | 2025-11-28 | 国家科学研究中心 | 3,5-二氨基三唑衍生物及其用于治疗眼部疾病的用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1403866A (en) | 1971-12-06 | 1975-08-28 | Wyeth John & Brother Ltd | Derivatives of 3-amino-1,2,4-triazoles |
| EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
| JP2002241368A (ja) | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
| GB9918180D0 (en) * | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
| PL363316A1 (en) * | 2000-12-22 | 2004-11-15 | Ortho Mc Neil Pharmaceutical, Inc. | Substituted triazole diamine derivatives as kinase inhibitors |
| DE10123586A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| TW201041580A (en) | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| BR0309688A (pt) | 2002-05-03 | 2005-02-22 | Janssen Pharmaceutica Nv | Microemulsões poliméricas |
| CA2501719C (en) | 2002-08-06 | 2013-02-05 | Toray Industries, Inc. | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| AU2003286746A1 (en) * | 2002-10-29 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| EP1663211B1 (en) | 2003-08-06 | 2010-01-20 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| CA2555825A1 (en) | 2004-02-11 | 2005-08-25 | Janssen Pharmaceutica N.V. | Process for the preparation of substituted triazole compounds |
| CA2580610C (en) * | 2004-09-17 | 2013-07-09 | Vertex Pharmaceuticals Incorporated | Diaminotriazole compounds useful as protein kinase inhibitors |
| DE602005024293D1 (de) | 2004-10-21 | 2010-12-02 | Vertex Pharma | Triazole als hemmer von proteinkinasen |
| WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| US8097630B2 (en) * | 2006-10-10 | 2012-01-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors |
| PL2078010T3 (pl) * | 2006-12-29 | 2014-07-31 | Rigel Pharmaceuticals Inc | Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl |
| US9650391B2 (en) | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
| CA2710230C (en) * | 2006-12-29 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| ES2558477T3 (es) * | 2006-12-29 | 2016-02-04 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos útiles como inhibidores de AXL |
| ES2406930T3 (es) * | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
| CA2681516A1 (en) * | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of janus kinases |
| EA200901654A1 (ru) | 2007-06-15 | 2010-06-30 | Айрм Ллк | Ингибиторы и способы с их использованием |
| SI2205592T1 (sl) * | 2007-10-26 | 2013-09-30 | Rigel Pharmaceuticals, Inc. | Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji |
| MX2010008926A (es) * | 2008-02-15 | 2011-02-23 | Rigel Pharmaceuticals Inc | Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas. |
| EP2326641B1 (en) * | 2008-07-09 | 2014-09-03 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2730251C (en) * | 2008-07-09 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| US8546433B2 (en) * | 2009-01-16 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
-
2007
- 2007-12-28 US US11/966,894 patent/US9650391B2/en active Active
- 2007-12-28 EP EP07866122.0A patent/EP2074115B1/en active Active
- 2007-12-28 CN CN2007800489092A patent/CN101622248B/zh not_active Expired - Fee Related
- 2007-12-28 EP EP12002451.8A patent/EP2484679B1/en not_active Not-in-force
- 2007-12-28 ES ES07866122.0T patent/ES2672172T3/es active Active
- 2007-12-28 CA CA2710046A patent/CA2710046C/en active Active
- 2007-12-28 WO PCT/US2007/089153 patent/WO2008083354A1/en not_active Ceased
- 2007-12-28 ES ES12002451.8T patent/ES2607065T3/es active Active
- 2007-12-28 AU AU2007342005A patent/AU2007342005A1/en not_active Abandoned
- 2007-12-28 JP JP2009544313A patent/JP5567837B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-04 US US13/644,738 patent/US8796259B2/en active Active
-
2014
- 2014-02-12 JP JP2014024758A patent/JP5890445B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5890445B2 (ja) | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール | |
| JP6253631B2 (ja) | Axlインヒビターとして有用な置換トリアゾール | |
| JP2010514809A5 (enExample) | ||
| JP5797792B2 (ja) | Axlインヒビターとして有用な多環式ヘテロアリール置換トリアゾール | |
| JP5635909B2 (ja) | Axl阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール | |
| HK1174631B (en) | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | |
| HK1132737B (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |